ABSCI CORP (ABSI) Stock Price & Overview
NASDAQ:ABSI • US00091E1091
Current stock price
The current stock price of ABSI is 3.06 USD. Today ABSI is down by -2.86%. In the past month the price increased by 18.15%. In the past year, price increased by 34.21%.
ABSI Key Statistics
- Market Cap
- 460.132M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.88
- Dividend Yield
- N/A
ABSI Stock Performance
ABSI Stock Chart
ABSI Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI turns out to be only a medium performer in the overall market: it outperformed 56.6% of all stocks.
ABSI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ABSI. While ABSI has a great health rating, there are worries on its profitability.
ABSI Earnings
On March 24, 2026 ABSI reported an EPS of -0.23 and a revenue of 650.00K. The company missed EPS expectations (-16.06% surprise) and missed revenue expectations (-42.07% surprise).
ABSI Forecast & Estimates
15 analysts have analysed ABSI and the average price target is 8.21 USD. This implies a price increase of 168.19% is expected in the next year compared to the current price of 3.06.
For the next year, analysts expect an EPS growth of 19.03% and a revenue growth 313.07% for ABSI
ABSI Groups
Sector & Classification
ABSI Financial Highlights
Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 5.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.25% | ||
| ROE | -60.8% | ||
| Debt/Equity | 0 |
ABSI Ownership
ABSI Latest News, Press Relases and Analysis
ABSI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABSI
Company Profile
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Company Info
IPO: 2021-07-22
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON US
CEO: Sean McClain
Employees: 156
Phone: 13026587581
ABSCI CORP / ABSI FAQ
What does ABSCI CORP do?
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
What is the stock price of ABSCI CORP today?
The current stock price of ABSI is 3.06 USD. The price decreased by -2.86% in the last trading session.
What is the dividend status of ABSCI CORP?
ABSI does not pay a dividend.
What is the ChartMill rating of ABSCI CORP stock?
ABSI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is ABSCI CORP worth?
ABSCI CORP (ABSI) has a market capitalization of 460.13M USD. This makes ABSI a Small Cap stock.
Who owns ABSCI CORP?
You can find the ownership structure of ABSCI CORP (ABSI) on the Ownership tab.
What is the Short Interest ratio of ABSCI CORP (ABSI) stock?
The outstanding short interest for ABSCI CORP (ABSI) is 29.26% of its float.